Oncimmune Holdings PLC Posting of Circular and Notice of General Meeting
October 23 2024 - 10:12AM
RNS Regulatory News
RNS Number : 3571J
Oncimmune Holdings PLC
23 October 2024
Oncimmune Holdings
plc
("Oncimmune" or the "Company")
Posting of Circular and
Notice of General Meeting
Oncimmune Holdings plc (AIM:
ONC.L), a leading autoantibody profiling company providing research
services to the pharmaceutical and biotechnology industry to enable
the delivery of precision medicine, announces that, further to its
announcement of 18 October 2024 containing details of the
Fundraising and Debt Restructuring (the "Launch Announcement"), the
Circular providing further details of the Fundraising and Debt
Restructuring and convening the General Meeting has been posted to
Shareholders today.
The Circular contains a notice of
the General Meeting which is to be held at the offices of Cavendish
Financial Plc, 1 Bartholomew Close, London EC1A 7BL, at 11:00 a.m.
on 8 November 2024 to approve the resolutions required to, inter
alia, implement the Fundraising and the Debt
Restructuring.
The Circular and Form of Proxy
(which will be sent to Shareholders along with the Circular) will
also shortly be available on the Company's website
www.oncimmune.com.
Capitalised terms not otherwise defined in the text of this
announcement have the meanings given to them in the Launch
Announcement.
For
further information:
Oncimmune Holdings plc
contact@oncimmune.com
Cavendish Capital Markets Limited (Nominated Adviser and Joint
Broker)
Geoff Nash, Callum Davidson, Trisyia
Jamaludin (Corporate Finance)
Nigel Birks, Life Science Specialist
Sales
Ondraya Swanson (ECM)
+44 (0) 20 7220 0500
Zeus (Joint Broker)
Dominic King, Dan Bate
+44 (0)20 3829 5000
About Oncimmune
Oncimmune is a precision medicine
company, specialising in analysing immune interactions through the
autoantibody profile. Taking a platform approach to generating
insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations
(CROs) to discover novel biomarkers for the development of more
targeted and effective therapies across many immune-mediated
diseases. Our mission at Oncimmune is to enable precision medicine.
We help our partners to discover novel biomarkers, drug targets and
predict treatment efficacy through the application of our platform.
We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of
experience in the field. Our aim is to make this an essential tool
in drug discovery and development.
Oncimmune is headquartered in the
UK, with its discovery and development facility based in Dortmund,
Germany and a business development team based in the US and
Europe.
For more information,
visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NOGPPGUGUUPCGAW
Oncimmune (LSE:ONC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From Dec 2023 to Dec 2024
